Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST-Elevation Acute Coronary Syndromes
- 1 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 101 (4) , 366-371
- https://doi.org/10.1161/01.cir.101.4.366
Abstract
Background—In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an acute coronary syndrome (uns...Keywords
This publication has 3 references indexed in Scilit:
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Cost-Effectiveness in Health and MedicinePublished by Oxford University Press (OUP) ,1996
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995